MX2020011779A - Anticuerpos para el tratamiento del cancer. - Google Patents

Anticuerpos para el tratamiento del cancer.

Info

Publication number
MX2020011779A
MX2020011779A MX2020011779A MX2020011779A MX2020011779A MX 2020011779 A MX2020011779 A MX 2020011779A MX 2020011779 A MX2020011779 A MX 2020011779A MX 2020011779 A MX2020011779 A MX 2020011779A MX 2020011779 A MX2020011779 A MX 2020011779A
Authority
MX
Mexico
Prior art keywords
cancer
antibodies
treatment
cancer expressing
expressing claudin
Prior art date
Application number
MX2020011779A
Other languages
English (en)
Inventor
Maria Kreuzberg
Michael Erdeljan
Michael Koslowski
Korden Walter
Stefan Wöll
Bernd Hubner
Michael Weichel
Özlem Türeci
Ugur Sahin
Original Assignee
Ganymed Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag
Publication of MX2020011779A publication Critical patent/MX2020011779A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Anticuerpos que son útiles como productos terapéuticos para tratar y/o prevenir enfermedades que se asocian con células que expresan CLDN6, incluyendo enfermedades relacionadas con tumores tales como cáncer de ovario, cáncer de pulmón, cáncer gástrico, cáncer de mama, cáncer hepático, cáncer pancreático, cáncer de piel, melanoma maligno, cáncer de cabeza y cuello, sarcoma, cáncer de ducto biliar, cáncer de vejiga urinaria, cáncer de riñón, cáncer de colon, coriocarcinoma de placenta, cáncer de cérvix, cáncer de testículo, y cáncer de útero.
MX2020011779A 2011-05-13 2013-11-08 Anticuerpos para el tratamiento del cancer. MX2020011779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486071P 2011-05-13 2011-05-13
EP11004004 2011-05-13

Publications (1)

Publication Number Publication Date
MX2020011779A true MX2020011779A (es) 2020-11-24

Family

ID=47176322

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2013013053A MX341147B (es) 2011-05-13 2012-04-20 Anticuerpos para el tratamiento del cáncer que expresa cldn6.
MX2020001224A MX2020001224A (es) 2011-05-13 2013-11-08 Anticuerpos para el tratamiento del cancer.
MX2020011779A MX2020011779A (es) 2011-05-13 2013-11-08 Anticuerpos para el tratamiento del cancer.
MX2020011778A MX2020011778A (es) 2011-05-13 2013-11-08 Anticuerpos para el tratamiento del cancer.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2013013053A MX341147B (es) 2011-05-13 2012-04-20 Anticuerpos para el tratamiento del cáncer que expresa cldn6.
MX2020001224A MX2020001224A (es) 2011-05-13 2013-11-08 Anticuerpos para el tratamiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020011778A MX2020011778A (es) 2011-05-13 2013-11-08 Anticuerpos para el tratamiento del cancer.

Country Status (29)

Country Link
US (5) US9321842B2 (es)
EP (3) EP3421496A1 (es)
JP (3) JP6276176B2 (es)
KR (3) KR102072183B1 (es)
CN (3) CN107011440B (es)
AR (2) AR086306A1 (es)
AU (4) AU2012258087B2 (es)
BR (1) BR112013029212B1 (es)
CA (1) CA2832174C (es)
CY (2) CY1118608T1 (es)
DK (2) DK3026064T3 (es)
ES (1) ES2565063T3 (es)
HK (1) HK1195320A1 (es)
HR (2) HRP20160212T1 (es)
HU (1) HUE028603T2 (es)
IL (1) IL228738B (es)
LT (1) LT3026064T (es)
ME (1) ME02369B (es)
MX (4) MX341147B (es)
NZ (3) NZ741567A (es)
PL (2) PL3026064T3 (es)
RS (2) RS54627B1 (es)
RU (1) RU2676731C2 (es)
SG (1) SG193551A1 (es)
SI (2) SI2707390T1 (es)
SM (1) SMT201600064B (es)
UA (2) UA115969C2 (es)
WO (1) WO2012156018A1 (es)
ZA (1) ZA201307102B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6109475B2 (ja) 2008-11-28 2017-04-05 テラヴィア ホールディングス， インコーポレイテッド 従属栄養微生物における、用途に応じた油の生産
KR20110128316A (ko) 2009-02-20 2011-11-29 가니메드 파마슈티칼스 아게 암의 진단 및 치료를 위한 방법 및 조성물
US9487584B2 (en) 2009-11-11 2016-11-08 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
EP3421496A1 (en) 2011-05-13 2019-01-02 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
EP2888283B1 (en) 2012-08-24 2018-09-19 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
JP6515111B2 (ja) 2013-11-06 2019-05-22 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗クローディン抗体および使用方法
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
WO2015108203A1 (ja) * 2014-01-15 2015-07-23 株式会社オーダーメードメディカルリサーチ 抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物
RS58627B2 (sr) * 2014-04-01 2022-06-30 Biontech Cell&Gene Therapies Gmbh Klaudin-6-specifični imuno receptori i t-ćelijski epitopi
TW202313697A (zh) 2014-11-11 2023-04-01 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
MX2017005163A (es) 2014-11-17 2018-01-18 Arno Therapeutics Inc Composiciones de liberación prolongada de onapristona y métodos.
CN106146666B (zh) * 2015-03-26 2019-09-06 科济生物医药（上海）有限公司 靶向cldn6的免疫效应细胞及其制备方法和应用
CN105504051B (zh) * 2015-12-17 2019-08-30 北京天成新脉生物技术有限公司 狂犬病毒核蛋白单克隆抗体及其应用
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
EP3562844A1 (en) * 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
WO2019048040A1 (en) * 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
GB202103867D0 (en) * 2017-09-18 2021-05-05 Univ California Claudin6 antibodies and methods of treating cancer
TWI820044B (zh) 2017-09-29 2023-11-01 日商第一三共股份有限公司 抗體－吡咯并苯二氮呯衍生物複合體
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137
EP3735463A4 (en) * 2018-01-05 2022-03-02 Chugai Seiyaku Kabushiki Kaisha THERAPEUTIC AGENT INDUCING CYTOTOXICITY
KR102340989B1 (ko) * 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
SG11202108281UA (en) 2019-02-15 2021-08-30 Integral Molecular Inc Claudin 6 antibodies and uses thereof
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
CA3134055A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
TW202116805A (zh) 2019-07-10 2021-05-01 日商中外製藥股份有限公司 Claudin-6結合分子以及其用途
WO2021129927A1 (en) 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
CN111087465B (zh) * 2019-12-24 2020-12-08 广州医科大学 一种针对密蛋白6的抗体偶联药物及应用
MX2022012092A (es) 2020-03-31 2022-10-13 Chugai Pharmaceutical Co Ltd Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos.
AU2021374036A1 (en) * 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
CN117157319A (zh) 2021-03-09 2023-12-01 Xencor股份有限公司 结合cd3和cldn6的异二聚抗体
US20230008868A1 (en) * 2021-07-08 2023-01-12 Nippon Telegraph And Telephone Corporation User authentication device, user authentication method, and user authentication computer program
JPWO2023053282A1 (es) 2021-09-29 2023-04-06
CA3234897A1 (en) * 2021-10-14 2023-04-20 Kunle Odunsi Compositions and methods for use of recombinant t cell receptors against claudin 6
WO2023105005A1 (en) 2021-12-09 2023-06-15 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
WO2024046572A1 (en) 2022-09-01 2024-03-07 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
WO2024088325A1 (zh) * 2022-10-25 2024-05-02 科济生物医药（上海）有限公司 抗体及其应用
WO2024095964A1 (ja) * 2022-10-31 2024-05-10 アステラス製薬株式会社 Ｔｏｌｌ様受容体７／８デュアルアゴニスト化合物を含む抗体薬物複合体
CN116064622B (zh) * 2023-02-13 2023-10-13 优睿赛思(武汉)生物科技有限公司 Claudin6-mCherry报告基因CHO-K1稳转细胞株制备及应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946788A (en) 1985-06-11 1990-08-07 Ciba-Geigy Corporation Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000012708A2 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2003524384A (ja) * 1998-11-03 2003-08-19 アドヘレックス テクノロジーズ インコーポレイテッド クラウディン媒介機能を調節するための化合物および方法
AU3124000A (en) 1998-12-17 2000-07-03 Human Genome Sciences, Inc. 47 human secreted proteins
CA2361743A1 (en) 1999-02-22 2000-08-31 Michael G. Walker Genes associated with diseases of the colon
EP1185648B1 (en) 1999-06-02 2007-03-21 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1067182A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
WO2001053312A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001051513A2 (en) 2000-01-14 2001-07-19 Corixa Corporation Ovarian tumor-associated sequences
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004516013A (ja) 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
CA2416456A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
NZ524523A (en) 2000-08-03 2006-02-24 Therapeutic Human Polyclonals Production of humanized antibodies in transgenic animals
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP2000545B1 (en) 2001-06-20 2011-08-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of lung tumor
CA2379661A1 (en) 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
MXPA04010092A (es) 2002-04-16 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2003089451A2 (en) * 2002-04-22 2003-10-30 Dyax Corporation Antibodies specific for mucin polypeptide
US20070207142A1 (en) 2002-05-08 2007-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
JP2006516089A (ja) 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2004035607A2 (en) 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
WO2004060270A2 (en) 2002-10-18 2004-07-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
KR20060035608A (ko) 2003-05-30 2006-04-26 센토코 인코포레이티드 항 조직 인자 항체로 종양 성장을 저해하는 방법
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20080305493A1 (en) 2004-03-08 2008-12-11 Avalon Pharmaceuticals Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
DE102005025041A1 (de) 2005-05-30 2006-12-07 Bell Flavors & Fragrances Duft Und Aroma Gmbh Mittel zur Anwendung in Spülmaschinen sowie Vorrichtung für dessen dosierte Einbringung während der Spül- und Trocknungsphasen
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009025759A1 (en) * 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
WO2009028663A1 (ja) * 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
US9274119B2 (en) * 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
EP2285392A4 (en) 2008-04-11 2012-06-06 Bionovo Inc PROCEDURE AGAINST CANCER WITH EXTRACTS FROM GLEDITSIA SINENSIS LAM
WO2010043650A2 (en) 2008-10-14 2010-04-22 Ablynx Nv Amino acid sequences directed against cellular receptors for viruses and bacteria
DE102009026966A1 (de) 2008-12-18 2010-07-01 Robert Bosch Gmbh Betrieb eines Bremskraftverstärkers als Pedalsimulator
JP2010178650A (ja) 2009-02-04 2010-08-19 Univ Of Tokyo 固形癌の再発予測のための試験方法および再発予防剤
KR20110128316A (ko) 2009-02-20 2011-11-29 가니메드 파마슈티칼스 아게 암의 진단 및 치료를 위한 방법 및 조성물
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
US9487584B2 (en) 2009-11-11 2016-11-08 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
WO2011105551A1 (ja) 2010-02-26 2011-09-01 国立大学法人大阪大学 癌幹細胞の検出方法、及び癌の治療剤または再発予防剤
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3421496A1 (en) 2011-05-13 2019-01-02 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
WO2013035824A1 (ja) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞の分離
EP2605017A1 (de) 2011-12-16 2013-06-19 Protagen AG Markersequenzen für gynäkologisches Malignom und deren Verwendung
JP6448056B2 (ja) 2012-07-19 2019-01-09 アムジェン インコーポレイテッド ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells

Also Published As

Publication number Publication date
BR112013029212B1 (pt) 2020-05-19
KR102072183B1 (ko) 2020-02-03
MX2013013053A (es) 2014-05-27
JP6637083B2 (ja) 2020-01-29
HK1195320A1 (en) 2014-11-07
HRP20190014T1 (hr) 2019-02-22
LT3026064T (lt) 2019-01-25
AU2017204663A1 (en) 2017-07-27
JP2023089133A (ja) 2023-06-27
HUE028603T2 (en) 2016-12-28
IL228738B (en) 2018-10-31
AU2012258087B2 (en) 2017-07-20
CN103748112B (zh) 2017-02-15
KR20220116069A (ko) 2022-08-19
US10233253B2 (en) 2019-03-19
CN107090043A (zh) 2017-08-25
EP2707390A1 (en) 2014-03-19
EP3421496A1 (en) 2019-01-02
CA2832174A1 (en) 2012-11-22
RU2013155455A (ru) 2015-06-20
CY1118608T1 (el) 2017-07-12
US10919974B2 (en) 2021-02-16
NZ617214A (en) 2016-04-29
DK3026064T3 (en) 2019-01-14
CN103748112A (zh) 2014-04-23
PL2707390T3 (pl) 2016-06-30
UA115969C2 (uk) 2018-01-25
ME02369B (me) 2016-06-20
AR122771A2 (es) 2022-10-05
US20140127219A1 (en) 2014-05-08
NZ741567A (en) 2023-10-27
SMT201600064B (it) 2016-04-29
US9321842B2 (en) 2016-04-26
AU2017204663B2 (en) 2019-05-23
CA2832174C (en) 2024-02-27
CN107011440A (zh) 2017-08-04
US20190010244A1 (en) 2019-01-10
RU2018145274A (ru) 2019-01-24
KR102430870B1 (ko) 2022-08-09
BR112013029212A2 (pt) 2016-11-29
US20210179730A1 (en) 2021-06-17
NZ724296A (en) 2020-05-29
CN107090043B (zh) 2021-12-07
KR20200078692A (ko) 2020-07-01
US20160264677A1 (en) 2016-09-15
SI3026064T1 (sl) 2019-03-29
WO2012156018A1 (en) 2012-11-22
MX2020011778A (es) 2020-11-24
AU2012258087A1 (en) 2013-11-21
WO2012156018A8 (en) 2013-10-17
AU2019219797A1 (en) 2019-09-12
PL3026064T3 (pl) 2019-05-31
UA127584C2 (uk) 2023-10-25
AU2021277764A1 (en) 2021-12-23
CY1121085T1 (el) 2019-12-11
SI2707390T1 (sl) 2016-04-29
CN107011440B (zh) 2021-03-05
ZA201307102B (en) 2016-08-31
RS54627B1 (en) 2016-08-31
MX2020001224A (es) 2020-07-20
US20240101703A1 (en) 2024-03-28
ES2565063T3 (es) 2016-03-31
US11859008B2 (en) 2024-01-02
RS58087B1 (sr) 2019-02-28
EP2707390B1 (en) 2015-12-30
RU2676731C2 (ru) 2019-01-10
AR086306A1 (es) 2013-12-04
JP6276176B2 (ja) 2018-02-07
MX341147B (es) 2016-08-09
NZ706004A (en) 2016-12-23
EP3026064A1 (en) 2016-06-01
EP3026064B1 (en) 2018-10-17
JP2018095650A (ja) 2018-06-21
JP2014516956A (ja) 2014-07-17
SG193551A1 (en) 2013-10-30
IL228738A0 (en) 2013-12-31
DK2707390T3 (en) 2016-02-29
HRP20160212T1 (hr) 2016-05-06
AU2019219797B2 (en) 2021-09-09
KR20140033045A (ko) 2014-03-17

Similar Documents

Publication Publication Date Title
MX2020011778A (es) Anticuerpos para el tratamiento del cancer.
MX2020011790A (es) Anticuerpos especificos para claudina 6 (cldn6).
MX2020011795A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011771A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
MY184332A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
MY180626A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2015000129A (es) Derivados de pirimidin pirazolilo.
TN2012000434A1 (en) Biparatopic abeta binding polypeptides
MX350661B (es) Composiciones inmunoterapeuticas de levadura-brachyuri.
MX357010B (es) Anticuerpos monoclonales para tratamiento de cancer.
MX2009003137A (es) Procesos de latex.
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
SG10201810357WA (en) Ly75 as cancer therapeutic and diagnostic target
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
EP3736022A3 (en) Treatment and diagnosis of colon cancer
EP3722417A4 (en) CANCER SPHEROID MANUFACTURING METHOD, AND PROCESS FOR SELECTING PATIENTS WITH COLORECTAL CANCER
WO2011153243A3 (en) Anti-angiogenesis therapy for treating gastric cancer
GB2490849A8 (en) Di-asprin derivatives for use in the treatment of colorectal cancer
AP2012006181A0 (en) Targeting PAX2 for the treatment of breast cancer.
TR201821021T4 (tr) Kanser tedavi̇si̇ne yöneli̇k claudin 6 ekspresyonlu anti̇korlar.
TN2010000377A1 (en) Forms of rifaximin and uses thereof